This investment reinforces Icon’s ongoing commitment to increasing access to world-class, precision-led cancer care and marks the first installation of this full suite of comprehensive Varian hardware and software in the UK.
The technology will be rolled out across Icon Cancer Centre London and three new locations in Brighton, Warwickshire, and Derby, in partnership with Nuffield Health, with further installations planned to support Icon’s growing footprint in the region.
Icon Europe CEO, Aldo Rolfo said this technology will increase access to world-class care.
“At Icon, we’re market leaders in introducing the absolute latest in radiotherapy technologies and treatments and ensuring we increase access to world-class care to communities we serve,” said Aldo.
“This large investment with Varian enables us to continue leading in precision cancer care and improving access to treatment and better outcomes for patients across the UK.”
Enhancing patient experience and outcomes
The new agreement will introduce Varian’s most innovative technologies to UK patients, delivering faster treatment times, more precise imaging and delivery, and streamline workflows that aim to improve the overall treatment experience:
TrueBeam – a linear accelerator for known for its state-of-the-art technology that enhances accuracy and efficiency in cancer treatment.
RapidArc Dynamic (RAD) – a state-of-the-art planning and delivery platform that reduces treatment planning time by up to 70% while enhancing plan quality and reducing dose exposure to critical organs.
HyperSight – advanced cone-beam CT imaging delivering clearer, faster images, that enhance anatomical visualisation and support more precise treatment delivery, while also helping to streamline workflows by reducing image acquisition time.
IDENTIFY – real-time surface-guided radiotherapy (SGRT) that increases treatment accuracy and can significantly reduce, and in many cases eliminate, the need for permanents tattoo markings, a sometime unfriendly reminder of a patient’s diagnosis.
The first installations will take place at Icon Cancer Centre London, with other sites following later in 2026.
Icon Group’s UK Chief Medical Officer, Dr Penny Kechagioglou said this new technology is a game-changer.
“This technology marks a new benchmark for radiotherapy in the UK,” said Dr Kechagioglou.
“There is currently an underutilisation of radiotherapy treatment, with fewer than 30% of cancer patients receiving it, less than the global recommended rate of 40 – 50% of cancer diagnosis1.
“This is a real win for cancer patients who will benefit from timely access to highly advanced non-invasive radiotherapy designed to improve both patient experience and outcomes.”
Head of Varian, Arthur Kaindl is looking forward to rolling out this technology.
“We’re pleased to deepen our collaboration with Icon in the UK,” said Arthur.
“This partnership reflects the trust place in our technologies and teams to help transform the cancer care experience with purpose and precision, for every patient in the region and beyond. Together, we’re committed to delivering innovations that truly serves patients and brings us closer to a world without fear of cancer.”
Icon Group CEO, Mark Middleton OAM agrees.
“We’re really proud of our partnership with Varian which has enabled first-to-market treatments across Australia, New Zealand, Asia and now into the UK where cancer rates are on the rise,” said Mark.
“Varian is leading the way in advancing radiotherapy for both clinical teams and patients and together we’re breaking new ground and turning the dial on cancer, globally.”
We look forward to sharing more updates as these new technologies go live across the UK.
© 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners.
